S3. Cinicopathological features of simultaneous and metachronous bilateral breast cancer.
| Cinicopathological features | Synchronous | P | Metachronous | P | ||
| Left | Right | Left | Right | |||
| DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HR, hormone receptor; HER2+, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; NA, not applicable. | ||||||
| Histological type | 0.0442 | NA | ||||
| DCIS | 51 (16.8) | 67 (22.0) | 10 (10.6) | 7 (7.4) | ||
| LCIS | 0 (0) | 4 (1.3) | 0 (0) | 0 (0) | ||
| IDC | 203 (66.8) | 192 (63.2) | 53 (56.4) | 60 (63.8) | ||
| ILC | 9 (3.0) | 2 (0.7) | 2 (2.1) | 3 (3.2) | ||
| Other | 26 (8.5) | 22 (7.2) | 3 (3.2) | 13 (13.8) | ||
| NA | 15 (4.9) | 17 (5.6) | 26 (27.7) | 11 (11.7) | ||
| Malignancy grade | 0.2908 | 0.0651 | ||||
| I | 21 (6.9) | 25 (8.2) | 4 (4.2) | 1 (1.1) | ||
| II | 135 (44.4) | 124 (40.8) | 27 (28.7) | 28 (29.8) | ||
| III | 49 (16.1) | 38 (12.5) | 17 (18.1) | 25 (26.6) | ||
| Carcinoma in situ | 33 (10.9) | 47 (15.5) | 8 (8.5) | 6 (6.4) | ||
| Other | 34 (11.2) | 29 (9.5) | 9 (9.6) | 18 (19.1) | ||
| NA | 32 (10.5) | 41 (13.5) | 29 (30.9) | 16 (17.0) | ||
| Tumor location | 0.4986 | <0.0001 | ||||
| Upper inner | 58 (19.1) | 47 (15.5) | 9 (9.6) | 3 (3.2) | ||
| Low inner | 26 (8.6) | 22 (7.2) | 63 (67.0) | 5 (5.3) | ||
| Upper lateral | 132 (43.4) | 148 (48.7) | 0 (0) | 42 (44.7) | ||
| Low lateral | 36 (11.8) | 27 (8.9) | 0 (0) | 7 (7.4) | ||
| Nipple deep | 15 (4.9) | 19 (6.3) | 0 (0) | 20 (21.3) | ||
| NA | 37 (12.2) | 41 (13.5) | 22 (23.4) | 17 (18.1) | ||
| TNM stage | 0.0698 | 0.7178 | ||||
| 0 | 32 (10.5) | 48 (15.8) | 9 (9.6) | 4 (4.2) | ||
| I | 90 (29.6) | 103 (33.9) | 16 (17.0) | 22 (23.4) | ||
| II | 102 (33.6) | 83 (27.3) | 24 (25.5) | 24 (25.5) | ||
| III | 26 (8.6) | 30 (9.9) | 7 (7.4) | 7 (7.4) | ||
| IV | 11 (3.6) | 4 (1.3) | 1 (1.1) | 1 (1.1) | ||
| NA | 43 (14.1) | 36 (11.8) | 37 (39.4) | 36 (38.4) | ||
| Molecular subtype | 0.2403 | 0.9464 | ||||
| HR+ | 178 (58.6) | 182 (59.9) | 37 (39.4) | 40 (42.6) | ||
| HR+/HER2+ | 35 (11.5) | 45 (14.8) | 15 (16.0) | 14 (14.9) | ||
| HER2+ | 15 (4.9) | 13 (4.3) | 8 (8.5) | 9 (9.6) | ||
| TNBC | 36 (11.8) | 21 (6.9) | 10 (10.6) | 7 (7.4) | ||
| NA | 40 (13.2) | 43 (14.1) | 24 (25.5) | 24 (25.5) | ||
| Tumor site | 0.5703 | 0.6254 | ||||
| Single | 230 (75.7) | 244 (80.3) | 56 (59.6) | 57 (60.6) | ||
| Multiple | 29 (9.5) | 22 (7.2) | 4 (4.3) | 8 (8.5) | ||
| Multicenter | 14 (4.6) | 11 (3.6) | 1 (1.1) | 1 (1.1) | ||
| NA | 31 (10.2) | 27 (8.9) | 33 (35.1) | 28 (29.8) | ||